What is Macitentan used for?

Tenaya Therapeutics, Inc., a biotechnology company focused on the development of treatments for heart diseases, has announced promising preliminary results from its MyPEAK-1 clinical trial examining TN-201 gene therapy. This therapy is being developed as a potential treatment for hypertrophic cardiomyopathy (HCM) associated with the MYBPC3 gene, which leads to insufficient production of myosin-binding protein C (MyBP-C), a critical component in cardiac muscle function.

In the early phase of the clinical trial, three patients received the TN-201 gene therapy at a dosage of 3E13 vg/kg. This initial cohort has shown encouraging results, with TN-201 proving to be generally well tolerated. Notably, the delivery system using the AAV9 capsid has effectively facilitated the transduction of TN-201 into heart muscle cells. This resulted in observable increases in transgene RNA expression and MyBP-C protein levels over the course of the year.

Researching Tenaya Therapeutics Announces Positive Early Results from MyPEAK™-1 Trial for TN-201 in MYBPC3-Related Hypertrophic Cardiomyopathy beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore Tenaya Therapeutics Announces Positive Early Results from MyPEAK™-1 Trial for TN-201 in MYBPC3-Related Hypertrophic Cardiomyopathy with Hiro LS Researcher →

The trial indicated that biomarkers related to cardiac stress and damage largely remained stable, and some clinical indicators of the disease showed stability or improvement. However, more extended studies are required to comprehensively understand TN-201's effectiveness. Tenaya Therapeutics plans to continue monitoring the patients in the first cohort and anticipate gathering further data from a second cohort with a higher dose in 2025.

Dr. Milind Desai, a leading figure in cardiovascular medicine and an investigator for the MyPEAK-1 study, highlighted the severe nature of HCM in the initial patients, which severely affected their quality of life despite existing treatments. He noted that gene therapy could potentially halt or even reverse the progression of MYBPC3-associated HCM by addressing its genetic roots. The initial findings in the clinical trial have demonstrated both tolerability and early signs of protein expression, warranting further research.

Whit Tingley, Tenaya's Chief Medical Officer, expressed optimism regarding the emerging safety profile of TN-201 and the initial evidence of its effects, which support the continuation of the study with higher doses. The aim is to further explore the potential of TN-201 to stabilize or improve disease conditions over a more extended period.

The MyPEAK-1 trial involves a one-time intravenous infusion of TN-201, specifically targeting adults with symptomatic MYBPC3-associated non-obstructive HCM who are at high risk of sudden cardiac death, often necessitating an implantable cardiac defibrillator. The trial aims to enroll up to 24 participants, assessing both 3E13 and 6E13 vg/kg dosages in different patient cohorts.

Hypertrophic cardiomyopathy associated with the MYBPC3 gene is the most common genetic cause of this condition, affecting a significant portion of the population. The mutation leads to insufficient MyBP-C protein levels, causing the heart to become hypercontractile and the left ventricle to thicken, leading to symptoms like chest pain and shortness of breath. Currently, no approved treatments target the genetic causes of HCM directly.

TN-201 utilizes an AAV9-based delivery system to introduce a functional MYBPC3 gene into heart cells, increasing protein levels with the aim of halting or reversing the disease progress with a single dose. This therapy has been granted Fast Track, Orphan Drug, and Rare Pediatric Drug Designations by the U.S. FDA and also holds orphan medicinal product designation from the European Commission.

Tenaya Therapeutics, through its innovative platform, is developing a range of genetic treatments targeting both rare and more widespread heart diseases, with TN-201 being at the forefront of these efforts. The company's mission is to harness genetic insights and advanced engineering to create transformative therapies that address the root causes of heart disease.

Continue your Tenaya Therapeutics Announces Positive Early Results from MyPEAK™-1 Trial for TN-201 in MYBPC3-Related Hypertrophic Cardiomyopathy research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Questions to explore:

• What approved and investigational uses have been reported for Tenaya Therapeutics Announces Positive Early Results from MyPEAK™-1 Trial for TN-201 in MYBPC3-Related Hypertrophic Cardiomyopathy?
• What is the mechanism of action of Tenaya Therapeutics Announces Positive Early Results from MyPEAK™-1 Trial for TN-201 in MYBPC3-Related Hypertrophic Cardiomyopathy, and which targets or pathways are involved?
• Which clinical trials are evaluating Tenaya Therapeutics Announces Positive Early Results from MyPEAK™-1 Trial for TN-201 in MYBPC3-Related Hypertrophic Cardiomyopathy, and what outcomes have been reported?
• What patents, publications, and regulatory sources provide the latest evidence on Tenaya Therapeutics Announces Positive Early Results from MyPEAK™-1 Trial for TN-201 in MYBPC3-Related Hypertrophic Cardiomyopathy?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!